- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT01198912
Influence of Oral Doxycycline on Wound Healing After Endonasal Endoscopic Sinus Surgery for Chronic Rhinosinusitis With and Without Nasal Polyposis: a Double-blind Randomized Placebo-controlled Trial (DOXYPOSTOP)
14. juni 2018 opdateret af: University Hospital, Ghent
Influence of Oral Doxycycline on Wound Healing After Endonasal Endoscopic Sinus Surgery for Chronic Rhinosinusitis With and Without Nasal Polyposis: a Double-blind Randomized Placebo-controlled Trial.
This is a randomized, double blind, placebo controlled, parallel group, study in patients with chronic rhinosinusitis with or without nasal polyps.
The objective is to test the clinical efficacy of long-term low dose oral doxycycline on wound healing quality after endoscopic sinus surgery.
Studieoversigt
Status
Afsluttet
Betingelser
Intervention / Behandling
Undersøgelsestype
Interventionel
Tilmelding (Faktiske)
33
Fase
- Fase 2
Kontakter og lokationer
Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.
Deltagelseskriterier
Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.
Berettigelseskriterier
Aldre berettiget til at studere
18 år og ældre (Voksen, Ældre voksen)
Tager imod sunde frivillige
Ingen
Køn, der er berettiget til at studere
Alle
Beskrivelse
Inclusion Criteria:
- at least 18 years of age, of either sex and any race
- diagnosis of chronic rhinosinusitis with or without nasal polyposis according to the EPOS guidelines research
- Subjects should be regularly scheduled for bilateral functional endonasal endoscopic sinus surgery
- Subjects must be in good health, free of any clinically significant disease that would interfere with the study schedule or procedures or compromise his/her safety.
- Subjects must be willing to give informed consent and adhere to visit schedules, medication restrictions, and agree to perform daily diary entries.
- Nonpregnant women of childbearing potential must use a medically acceptable, adequate form of birth control.
Exclusion Criteria:
- Women must not be pregnant, breast feeding, or premenarcheal.
- Subjects who have required oral corticosteroids within the previous four weeks prior to surgery.
- Subjects who have required nasal corticosteroids within the previous one week prior to surgery.
- Subjects with known allergic reaction on tetracyclines, diabetes (type 1 and 2), renal insufficiency, severe liver disease, systemic diseases affecting the nose (e.g. M. Wegener), prior surgeries of the paranasal sinuses.
Patients with the following diseases should be excluded :
- Cystic fibrosis based on positive sweat test or DNA alleles
- Gross immunodeficiency (congenital or acquired)
- congenital mucociliary problems e.g. primary ciliary dyskinesia (PCD)
- Non-invasive fungal balls and invasive fungal disease
- systemic vasculitis and granulomatous diseases
- Cocaine abuse
- Neoplasia
Studieplan
Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Dobbelt
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Placebo komparator: placebo
|
during 56 days
|
|
Eksperimentel: doxycycline 100 mg
|
during 56 days
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Endoscopic evaluation of quality and speed of wound healing
Tidsramme: at 3 months after first drug intake
|
at 3 months after first drug intake
|
|
Recurrence of nasal polyps
Tidsramme: at 3 months after first drug intake
|
at 3 months after first drug intake
|
|
Recurrence of nasal polyps
Tidsramme: at 6 months after first drug intake
|
at 6 months after first drug intake
|
Sekundære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
nasal and exhaled NO
Tidsramme: at 3 months after first drug intake
|
at 3 months after first drug intake
|
|
nasal and exhaled NO
Tidsramme: at 6 months after first drug intake
|
at 6 months after first drug intake
|
|
subjective assessment of the wound healing
Tidsramme: at 3 months after first drug intake
|
at 3 months after first drug intake
|
|
subjective assessment of the wound healing
Tidsramme: at 6 months after first drug intake
|
at 6 months after first drug intake
|
|
chronic rhinosinusitis symptoms by the patients
Tidsramme: at 3 months after first drug intake
|
at 3 months after first drug intake
|
|
chronic rhinosinusitis symptoms by the patients
Tidsramme: at 6 months after first drug intake
|
at 6 months after first drug intake
|
|
Questionnaires: SNOT 22, RSOM, SF36 asthma control questionnaire
Tidsramme: at 3 months after first drug intake
|
at 3 months after first drug intake
|
|
Questionnaires: SNOT 22, RSOM, SF36 asthma control questionnaire
Tidsramme: at 6 months after first drug intake
|
at 6 months after first drug intake
|
|
inflammatory mediators in nasal fluid as well as in serum
Tidsramme: at 3 months after first drug intake
|
at 3 months after first drug intake
|
|
inflammatory mediators in nasal fluid as well as in serum
Tidsramme: at 6 months after first drug intake
|
at 6 months after first drug intake
|
Samarbejdspartnere og efterforskere
Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.
Sponsor
Efterforskere
- Ledende efterforsker: Claus Bachert, MD, PhD, University Hospital Ghent, Belgium
Publikationer og nyttige links
Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.
Hjælpsomme links
Datoer for undersøgelser
Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.
Studer store datoer
Studiestart (Faktiske)
22. november 2011
Primær færdiggørelse (Faktiske)
6. september 2016
Studieafslutning (Faktiske)
6. februar 2017
Datoer for studieregistrering
Først indsendt
8. september 2010
Først indsendt, der opfyldte QC-kriterier
9. september 2010
Først opslået (Skøn)
10. september 2010
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
15. juni 2018
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
14. juni 2018
Sidst verificeret
1. juni 2018
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
- Infektioner
- Luftvejsinfektioner
- Luftvejssygdomme
- Otorhinolaryngologiske sygdomme
- Patologiske Tilstande, Anatomiske
- Paranasale bihulesygdomme
- Næsesygdomme
- Polypper
- Bihulebetændelse
- Næsepolypper
- Anti-infektionsmidler
- Antibakterielle midler
- Antiprotozoale midler
- Antiparasitære midler
- Antimalariamidler
- Doxycyclin
Andre undersøgelses-id-numre
- 2010/384
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .